ENTA
Enanta Pharmaceuticals, Inc.
Price Chart
Latest Quote
$12.66
+0.02 (+0.16%)
Current Price
| Previous Close | $12.64 |
| Open | $12.87 |
| Day High | $13.06 |
| Day Low | $12.48 |
| Volume | 254,121 |
Stock Information
| Shares Outstanding | 29.08M |
| Total Debt | $186.62M |
| Cash Equivalents | $163.77M |
| Revenue | $69.21M |
| Net Income | $-61.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $368.13M |
| EPS (TTM) | $-2.60 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $390.98M |
| Sales | $69.21M |
| Income | $-61.98M |
| Book/sh | $4.01 |
| Cash/sh | $5.63 |
| Employees | 120 |
Financial Ratios
| Quick Ratio | 3.69 |
| Current Ratio | 3.84 |
| Debt/Eq | 160.07 |
Returns & Margins
| ROA | -11.84% |
| ROE | -59.00% |
| Gross Margin | 100.00% |
| Operating Margin | -69.07% |
| Profit Margin | -89.55% |
Ownership
| Insider Ownership | 4.68% |
| Institutional Ownership | 92.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.48 |
| P/S | 5.32 |
| P/B | 3.16 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.14 |
Technical Indicators
| SMA20 | $12.31 |
| SMA50 | $13.38 |
| SMA200 | $12.70 |
| RSI | 45.81 |
| ATR | 0.8132 |
| Shares Float | 20.06M |
| Short Float | 9.36% |
| Short Ratio | 10.42 |
| Volatility | 0.99 |
| Rel Volume | 1.29 |
Performance History
| Week | +9.99% |
| Month | -7.99% |
| Quarter | -2.62% |
| 6 Months | -14.75% |
| YTD | -12.21% |
| Year | +79.57% |
| 3 Years | -48.97% |
| 5 Years | -73.14% |
| 10 Years | -46.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $12.66 | 254,100 |
| 2026-06-17 | $12.64 | 171,400 |
| 2026-06-16 | $12.07 | 142,700 |
| 2026-06-15 | $11.44 | 114,000 |
| 2026-06-12 | $11.90 | 190,300 |
| 2026-06-11 | $11.51 | 263,200 |
| 2026-06-10 | $11.70 | 143,000 |
| 2026-06-09 | $11.35 | 131,300 |
| 2026-06-08 | $11.07 | 158,100 |
| 2026-06-05 | $11.28 | 135,100 |
| 2026-06-04 | $11.73 | 208,600 |
| 2026-06-03 | $11.24 | 372,300 |
| 2026-06-02 | $12.03 | 197,000 |
| 2026-06-01 | $12.67 | 198,300 |
| 2026-05-29 | $13.16 | 188,000 |
| 2026-05-28 | $13.23 | 165,600 |
| 2026-05-27 | $13.19 | 295,400 |
| 2026-05-26 | $13.53 | 330,500 |
| 2026-05-22 | $13.95 | 141,300 |
| 2026-05-21 | $13.83 | 141,500 |
| 2026-05-20 | $13.61 | 161,200 |
| 2026-05-19 | $13.76 | 203,900 |
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
đ° Latest News
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-11T21:10:02Z
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T21:55:03Z
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Zacks âĸ 2026-05-07T13:02:00Z
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
MarketBeat âĸ 2026-03-15T22:41:07Z
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Zacks âĸ 2026-02-12T17:00:02Z
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-02-09T22:05:02Z
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
Associated Press Finance âĸ 2026-02-09T21:06:51ZJPM26: Enanta outlines strategy to lead in RSV therapeutics
Pharmaceutical Technology âĸ 2026-01-15T22:39:17Z
Enanta Pharmaceuticals Insider Ups Holding During Year
Simply Wall St. âĸ 2026-01-01T13:03:56Z
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
Zacks âĸ 2025-12-26T13:42:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $65,324,000 | $67,635,000 | $79,204,000 | $86,160,000 |
| Operating Revenue | $65,324,000 | $67,635,000 | $79,204,000 | $86,160,000 |
| Expenses | ||||
| Interest Expense | $7,681,000 | $10,940,000 | $5,148,000 | $0 |
| Total Expenses | $150,673,000 | $189,326,000 | $216,411,000 | $210,004,000 |
| Other Income Expense | $39,000 | $73,000 | - | $83,000 |
| Net Non Operating Interest Income Expense | $1,761,000 | $3,830,000 | $6,212,000 | $1,573,000 |
| Interest Expense Non Operating | $7,681,000 | $10,940,000 | $5,148,000 | $0 |
| Operating Expense | $150,673,000 | $189,326,000 | $216,411,000 | $210,004,000 |
| General And Administrative Expense | $43,933,000 | $57,850,000 | $52,887,000 | $45,482,000 |
| Other Non Operating Income Expenses | - | - | - | $83,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Net Interest Income | $1,761,000 | $3,830,000 | $6,212,000 | $1,573,000 |
| Interest Income | $9,442,000 | $14,770,000 | $11,360,000 | $1,573,000 |
| Normalized Income | $-81,927,220 | $-116,116,905 | $-133,816,000 | $-121,837,668 |
| Net Income From Continuing And Discontinued Operation | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Total Operating Income As Reported | $-85,349,000 | $-121,691,000 | $-137,207,000 | $-123,844,000 |
| Net Income Common Stockholders | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Net Income | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Net Income Including Noncontrolling Interests | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Net Income Continuous Operations | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Pretax Income | $-83,549,000 | $-117,788,000 | $-130,995,000 | $-122,188,000 |
| Interest Income Non Operating | $9,442,000 | $14,770,000 | $11,360,000 | $1,573,000 |
| Operating Income | $-85,349,000 | $-121,691,000 | $-137,207,000 | $-123,844,000 |
| Per Share | ||||
| Diluted EPS | $-3.84 | $-5.48 | $-6.38 | $-5.91 |
| Basic EPS | $-3.84 | $-5.48 | $-6.38 | $-5.91 |
| Other | ||||
| Tax Effect Of Unusual Items | $780 | $1,095 | $0 | $332 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-71,321,000 | $-104,585,000 | $-123,476,000 | $-119,298,000 |
| Total Unusual Items | $39,000 | $73,000 | - | $83,000 |
| Total Unusual Items Excluding Goodwill | $39,000 | $73,000 | - | $83,000 |
| Reconciled Depreciation | $4,586,000 | $2,336,000 | $2,371,000 | $2,973,000 |
| EBITDA (Bullshit earnings) | $-71,282,000 | $-104,512,000 | $-123,476,000 | $-119,215,000 |
| EBIT | $-75,868,000 | $-106,848,000 | $-125,847,000 | $-122,188,000 |
| Diluted Average Shares | $21,336,000 | $21,157,000 | $20,969,000 | $20,603,000 |
| Basic Average Shares | $21,336,000 | $21,157,000 | $20,969,000 | $20,603,000 |
| Diluted NI Availto Com Stockholders | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Tax Provision | $-1,660,000 | $-1,743,000 | $2,821,000 | $-433,000 |
| Gain On Sale Of Security | $39,000 | $73,000 | - | $83,000 |
| Research And Development | $106,740,000 | $131,476,000 | $163,524,000 | $164,522,000 |
| Selling General And Administration | $43,933,000 | $57,850,000 | $52,887,000 | $45,482,000 |
| Other Gand A | $43,933,000 | $57,850,000 | $52,887,000 | $45,482,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Total Assets | $280,732,000 | $376,652,000 | $462,275,000 | $375,410,000 |
| Total Non Current Assets | $76,396,000 | $76,800,000 | $39,484,000 | $63,697,000 |
| Other Non Current Assets | $3,452,000 | $3,454,000 | $4,771,000 | $4,664,000 |
| Current Assets | $204,336,000 | $299,852,000 | $422,791,000 | $311,713,000 |
| Other Current Assets | $8,590,000 | $12,413,000 | $13,263,000 | $13,445,000 |
| Restricted Cash | $0 | $608,000 | $0 | - |
| Receivables | $6,882,000 | $38,645,000 | $39,618,000 | $49,036,000 |
| Taxes Receivable | $0 | $31,999,000 | $31,004,000 | $28,718,000 |
| Accounts Receivable | $6,882,000 | $6,646,000 | $8,614,000 | $20,318,000 |
| Cash Cash Equivalents And Short Term Investments | $188,864,000 | $248,186,000 | $369,910,000 | $249,232,000 |
| Cash And Cash Equivalents | $32,298,000 | $37,233,000 | $85,388,000 | $43,994,000 |
| Investmentin Financial Assets | - | - | $0 | $29,285,000 |
| Prepaid Assets | - | - | - | $13,445,000 |
| Debt | ||||
| Total Debt | $57,903,000 | $55,467,000 | $26,513,000 | $25,263,000 |
| Long Term Debt And Capital Lease Obligation | $54,757,000 | $53,943,000 | $21,238,000 | $22,372,000 |
| Current Debt And Capital Lease Obligation | $3,146,000 | $1,524,000 | $5,275,000 | $2,891,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $216,015,000 | $247,838,000 | $245,540,000 | $54,076,000 |
| Total Non Current Liabilities Net Minority Interest | $167,460,000 | $190,303,000 | $182,753,000 | $24,249,000 |
| Other Non Current Liabilities | $111,392,000 | $135,010,000 | $160,092,000 | $454,000 |
| Current Liabilities | $48,555,000 | $57,535,000 | $62,787,000 | $29,827,000 |
| Other Current Liabilities | $30,710,000 | $34,462,000 | $35,076,000 | - |
| Payables And Accrued Expenses | $14,699,000 | $21,549,000 | $22,436,000 | $26,936,000 |
| Payables | $1,948,000 | $8,002,000 | $4,097,000 | $6,000,000 |
| Accounts Payable | $1,948,000 | $8,002,000 | $4,097,000 | $6,000,000 |
| Equity | ||||
| Common Stock Equity | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Total Equity Gross Minority Interest | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Stockholders Equity | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Gains Losses Not Affecting Retained Earnings | $-339,000 | $302,000 | $-1,174,000 | $-3,724,000 |
| Other Equity Adjustments | $-339,000 | $302,000 | $-1,174,000 | $-3,724,000 |
| Retained Earnings | $-404,929,000 | $-323,040,000 | $-206,995,000 | $-73,179,000 |
| Preferred Securities Outside Stock Equity | $1,311,000 | $1,350,000 | $1,423,000 | $1,423,000 |
| Other | ||||
| Ordinary Shares Number | $21,387,000 | $21,194,000 | $21,059,000 | $20,791,000 |
| Share Issued | $21,387,000 | $21,194,000 | $21,059,000 | $20,791,000 |
| Tangible Book Value | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Invested Capital | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Working Capital | $155,781,000 | $242,317,000 | $360,004,000 | $281,886,000 |
| Capital Lease Obligations | $57,903,000 | $55,467,000 | $26,513,000 | $25,263,000 |
| Total Capitalization | $64,717,000 | $128,814,000 | $216,735,000 | $321,334,000 |
| Additional Paid In Capital | $469,771,000 | $451,340,000 | $424,693,000 | $398,029,000 |
| Capital Stock | $214,000 | $212,000 | $211,000 | $208,000 |
| Common Stock | $214,000 | $212,000 | $211,000 | $208,000 |
| Long Term Capital Lease Obligation | $54,757,000 | $53,943,000 | $21,238,000 | $22,372,000 |
| Current Capital Lease Obligation | $3,146,000 | $1,524,000 | $5,275,000 | $2,891,000 |
| Current Accrued Expenses | $12,751,000 | $13,547,000 | $18,339,000 | $20,936,000 |
| Net PPE | $72,944,000 | $73,346,000 | $34,713,000 | $29,748,000 |
| Accumulated Depreciation | $-23,805,000 | $-25,047,000 | $-23,745,000 | $-21,858,000 |
| Gross PPE | $96,749,000 | $98,393,000 | $58,458,000 | $51,606,000 |
| Leases | $38,200,000 | $13,975,000 | $13,804,000 | $7,276,000 |
| Construction In Progress | $0 | $22,748,000 | $1,273,000 | $2,556,000 |
| Other Properties | $37,549,000 | $40,658,000 | $22,794,000 | $23,575,000 |
| Machinery Furniture Equipment | $21,000,000 | $21,012,000 | $20,587,000 | $18,199,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $156,566,000 | $210,953,000 | $284,522,000 | $205,238,000 |
| Investments And Advances | - | - | $0 | $29,285,000 |
| Available For Sale Securities | - | - | - | $29,285,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-32,168,000 | $-96,712,000 | $-112,212,000 | $-86,907,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-19,272,000 | $-78,764,000 | $-103,154,000 | $-84,782,000 |
| Cash Flow From Continuing Operating Activities | $-19,272,000 | $-78,764,000 | $-103,154,000 | $-84,782,000 |
| Operating Gains Losses | $6,000 | $16,000 | $150,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-12,896,000 | $-17,948,000 | $-9,058,000 | $-2,125,000 |
| Investing Cash Flow | $40,347,000 | $58,235,000 | $-53,578,000 | $54,897,000 |
| Cash Flow From Continuing Investing Activities | $40,347,000 | $58,235,000 | $-53,578,000 | $54,897,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-26,618,000 | $-27,626,000 | $198,126,000 | $20,033,000 |
| Cash Flow From Continuing Financing Activities | $-26,618,000 | $-27,626,000 | $198,126,000 | $20,033,000 |
| Net Other Financing Charges | $-26,763,000 | $-27,773,000 | $195,918,000 | $-1,229,000 |
| Other | ||||
| Interest Paid Supplemental Data | $8,794,000 | $11,710,000 | $1,987,000 | $0 |
| Income Tax Paid Supplemental Data | $109,000 | $241,000 | $4,899,000 | $0 |
| End Cash Position | $35,658,000 | $41,201,000 | $89,356,000 | $47,962,000 |
| Beginning Cash Position | $41,201,000 | $89,356,000 | $47,962,000 | $57,814,000 |
| Changes In Cash | $-5,543,000 | $-48,155,000 | $41,394,000 | $-9,852,000 |
| Proceeds From Stock Option Exercised | $145,000 | $147,000 | $2,208,000 | $21,262,000 |
| Net Investment Purchase And Sale | $53,243,000 | $76,183,000 | $-44,520,000 | $57,022,000 |
| Sale Of Investment | $262,872,000 | $383,465,000 | $328,871,000 | $228,468,000 |
| Purchase Of Investment | $-209,629,000 | $-307,282,000 | $-373,391,000 | $-171,446,000 |
| Net PPE Purchase And Sale | $-12,896,000 | $-17,948,000 | $-9,058,000 | $-2,125,000 |
| Purchase Of PPE | $-12,896,000 | $-17,948,000 | $-9,058,000 | $-2,125,000 |
| Change In Working Capital | $39,909,000 | $7,130,000 | $8,024,000 | $6,789,000 |
| Change In Other Current Liabilities | $1,266,000 | $4,562,000 | $-2,358,000 | $-3,810,000 |
| Change In Other Current Assets | $4,310,000 | $6,805,000 | $4,491,000 | $4,172,000 |
| Change In Payables And Accrued Expense | $-1,253,000 | $-6,060,000 | $-3,709,000 | $-6,111,000 |
| Change In Accrued Expense | $58,000 | $-5,646,000 | $-2,558,000 | $-1,477,000 |
| Change In Payable | $-1,311,000 | $-414,000 | $-1,151,000 | $-4,634,000 |
| Change In Account Payable | $-1,311,000 | $-414,000 | $-1,151,000 | $-4,634,000 |
| Change In Prepaid Assets | $3,823,000 | $850,000 | $182,000 | $743,000 |
| Change In Receivables | $31,763,000 | $973,000 | $9,418,000 | $11,795,000 |
| Changes In Account Receivables | $-236,000 | $1,968,000 | $11,704,000 | $3,258,000 |
| Other Non Cash Items | $-952,000 | $2,142,000 | $-5,243,000 | $-929,000 |
| Stock Based Compensation | $18,565,000 | $26,795,000 | $28,216,000 | $26,969,000 |
| Amortization Of Securities | $503,000 | $-1,138,000 | $-2,856,000 | $1,171,000 |
| Depreciation Amortization Depletion | $4,586,000 | $2,336,000 | $2,371,000 | $2,973,000 |
| Depreciation And Amortization | $4,586,000 | $2,336,000 | $2,371,000 | $2,973,000 |
| Depreciation | $4,586,000 | - | - | - |
| Gain Loss On Sale Of PPE | $6,000 | $16,000 | $150,000 | $0 |
| Net Income From Continuing Operations | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 |
| Repayment Of Debt | - | $-27,479,000 | $0 | $0 |
| Net Issuance Payments Of Debt | - | $-27,479,000 | $0 | $0 |
| Net Long Term Debt Issuance | - | $-27,479,000 | $0 | $0 |
| Long Term Debt Payments | - | $-27,479,000 | $0 | $0 |
| Deferred Tax | - | - | $0 | $0 |
| Deferred Income Tax | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | - | $-604,000 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-18